- Home
- REX vs PHVS Comparison
REX vs PHVS Comparison
Compare REX & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REX
- PHVS
- Stock Information
- Founded
- REX 1980
- PHVS 2015
- Country
- REX United States
- PHVS Netherlands
- Employees
- REX N/A
- PHVS N/A
- Industry
- REX Major Chemicals
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- REX Industrials
- PHVS Health Care
- Exchange
- REX Nasdaq
- PHVS Nasdaq
- Market Cap
- REX 800.0M
- PHVS 894.8M
- IPO Year
- REX N/A
- PHVS 2021
- Fundamental
- Price
- REX $41.25
- PHVS $16.49
- Analyst Decision
- REX Strong Buy
- PHVS Strong Buy
- Analyst Count
- REX 1
- PHVS 5
- Target Price
- REX $55.00
- PHVS $41.60
- AVG Volume (30 Days)
- REX 122.7K
- PHVS 35.8K
- Earning Date
- REX 03-27-2025
- PHVS 04-09-2025
- Dividend Yield
- REX N/A
- PHVS N/A
- EPS Growth
- REX 37.28
- PHVS N/A
- EPS
- REX 3.82
- PHVS N/A
- Revenue
- REX $671,877,000.00
- PHVS N/A
- Revenue This Year
- REX N/A
- PHVS N/A
- Revenue Next Year
- REX $8.80
- PHVS N/A
- P/E Ratio
- REX $10.82
- PHVS N/A
- Revenue Growth
- REX N/A
- PHVS N/A
- 52 Week Low
- REX $39.02
- PHVS $15.21
- 52 Week High
- REX $60.79
- PHVS $28.17
- Technical
- Relative Strength Index (RSI)
- REX 44.37
- PHVS 36.48
- Support Level
- REX $41.34
- PHVS $17.01
- Resistance Level
- REX $44.10
- PHVS $17.94
- Average True Range (ATR)
- REX 1.25
- PHVS 0.71
- MACD
- REX 0.00
- PHVS -0.09
- Stochastic Oscillator
- REX 25.00
- PHVS 17.44
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.